Compound library / Fat Loss / GLP-1
Eli Lilly's investigational, long-acting, selective amylin receptor agonist (compound code LY3841136) dosed once weekly for obesity. Phase 2 data (2025) showed 9.5-20.1% weight reduction at 48 weeks with low GI side effects; Phase 3 enrollment targeted for late 2026.
| Category | Fat Loss / GLP-1 |
|---|---|
| Typical route | Subcutaneous |
| Half-life | Supports once-weekly dosing |
| Common dose range | Phase 2 trial doses: 1-9 mg/week, with some dose-escalation regimens |
| Typical cycle length | Not yet established outside trials |
BioHack Track models Eloralintide at a half-life of 168 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Not commercially available outside clinical trials.
N/A — investigational.
Still investigational, not FDA-approved; only available through clinical trial enrollment as of this writing. Source: Lilly Phase 2 results press release and Applied Clinical Trials Online, 2025-2026.
Track Eloralintide in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for Eloralintide — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.